Neumora Therapeutics Reports Q3 GAAP EPS of -$0.18, Exceeding Estimates
Neumora Therapeutics (NMRA) reported third-quarter earnings with a GAAP earnings per share (EPS) of -$0.18, slightly outperforming market expectations by $0.02. The results provide a narrow beat on the bottom line for the biotechnology company. As of September 30, 2026, Neumora reported having $85.7 million in cash and cash equivalents on its balance sheet. Despite the earnings beat, the company has opted not to provide updated guidance regarding its financial runway at this time.

Tickers: $NMRA
Topics: cash position earnings beat financial guidance
Read the full article at Seeking Alpha
Part of the story Neumora Therapeutics Reports Q3 GAAP EPS of -$0.18, Exceeding Estimates (3 articles)